Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Ohad BenjaminiDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Preetesh JainDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Long TrinhDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Wei QiaoDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Sara S. StromDepartment of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Susan LernerDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Xuemei WangDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Jan BurgerDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Alessandra FerrajoliDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Hagop KantarjianDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Susan O'BrienDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

William WierdaDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Zeev EstrovDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Michael KeatingDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]

Your download is now in progress and you may close this window